Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intellia Therapeutics

10.18
+0.45004.62%
Pre-market: 10.210.0300+0.29%07:41 EST
Volume:6.97M
Turnover:68.79M
Market Cap:1.18B
PE:-2.39
High:10.26
Open:9.59
Low:9.38
Close:9.73
52wk High:28.25
52wk Low:5.90
Shares:115.83M
Float Shares:102.00M
Volume Ratio:0.58
T/O Rate:6.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.2519
EPS(LYR):-5.2506
ROE:-52.11%
ROA:-28.51%
PB:1.58
PE(LYR):-1.94

Loading ...

Intellia Therapeutics Is Maintained at Market Outperform by Citizens

Dow Jones
·
Nov 07

Intellia Therapeutics price target lowered to $27 from $33 at Oppenheimer

TIPRANKS
·
Nov 07

Intellia Therapeutics Inc. : Oppenheimer Cuts Target Price to $27 From $33

THOMSON REUTERS
·
Nov 07

Intellia Therapeutics, Inc. : Wells Fargo Cuts Target Price to $12 From $17

THOMSON REUTERS
·
Nov 07

Intellia Therapeutics Cut to Underweight From Neutral by JP Morgan

Dow Jones
·
Nov 07

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, gold and silver miners

Reuters
·
Nov 07

BUZZ-Intellia falls after US FDA halts key heart disease trials following patient death

Reuters
·
Nov 07

Intellia Therapeutics price target lowered to $14 from $24 at Barclays

TIPRANKS
·
Nov 07

Cautious Hold Rating on Intellia Therapeutics Amid Safety Concerns and Regulatory Uncertainty

TIPRANKS
·
Nov 07

Intellia Therapeutics downgraded to Underweight from Neutral at JPMorgan

TIPRANKS
·
Nov 07

U.S. RESEARCH ROUNDUP-Blackline, Carmax, Expedia

Reuters
·
Nov 07

Intellia Therapeutics Inc : Baird Cuts Target Price to $4 From $9

THOMSON REUTERS
·
Nov 07

Intellia Therapeutics Q3 EPS $(0.92) Beats $(0.99) Estimate, Sales $13.782M Miss $15.185M Estimate

Benzinga
·
Nov 07

BRIEF-Intellia Therapeutics Q3 Net Income USD -101.324 Million

Reuters
·
Nov 07

Intellia Therapeutics Q3 Collaboration Revenue USD 13.782 Million

THOMSON REUTERS
·
Nov 07

William Blair Remains a Hold on Intellia Therapeutics (NTLA)

TIPRANKS
·
Nov 03

Cathie Wood Cuts Stake in Palantir Stock (PLTR) Ahead of Q3, Loads Up on Bullish (BLSH) and Intellia (NTLA)

TIPRANKS
·
Nov 01

Intellia Stock Downgraded After Trial Pause Raises Safety Concerns, BofA Says

MT Newswires Live
·
Nov 01

Intellia Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Oct 31

Intellia Therapeutics price target lowered to $9 from $14 at Wedbush

TIPRANKS
·
Oct 30